Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$4.22 CAD
Change Today -0.12 / -2.76%
Volume 6.5K
As of 3:59 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

nuvo research inc (NRI) Snapshot

Open
C$4.34
Previous Close
C$4.34
Day High
C$4.34
Day Low
C$4.21
52 Week High
01/29/15 - C$10.38
52 Week Low
05/28/14 - C$2.50
Market Cap
45.7M
Average Volume 10 Days
23.1K
EPS TTM
C$0.49
Shares Outstanding
10.8M
EX-Date
--
P/E TM
8.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVO RESEARCH INC (NRI)

Related News

No related news articles were found.

nuvo research inc (NRI) Related Businessweek News

No Related Businessweek News Found

nuvo research inc (NRI) Details

Nuvo Research Inc., a specialty pharmaceutical company, researches, develops, and commercializes pharmaceutical products in Europe, Asia, and South America. The company has four commercialized products; a pipeline of topical and transdermal products focusing on various therapeutic areas, including pain and dermatology; and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. Its topical pain products include Pennsaid, a non-steroidal anti-inflammatory drug that is used for the treatment of the pain of knee osteoarthritis; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of pain of knee osteoarthritis; and Pliaglis, a topical local anaesthetic cream, which provides local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal, as well as heated lidocaine/tetracaine patch, a topical patch that provides local dermal analgesia for superficial venous access and superficial dermatological procedures. The company’s immunology products comprise WF10, an immune system modulating drug containing chlorite and chlorate ions; and Oxoferin, a topical wound healing agent containing the active ingredient in WF10 at a lower concentration. The company was formerly known as Dimethaid Research Inc. and changed its name to Nuvo Research Inc. in September 2005. The company was founded in 1983 and is based in Mississauga, Canada.

66 Employees
Last Reported Date: 02/19/15
Founded in 1983

nuvo research inc (NRI) Top Compensated Officers

Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: C$289.7K
Chairman and Co-Chief Executive Officer
Total Annual Compensation: C$289.7K
Chief Financial Officer and Vice President
Total Annual Compensation: C$260.0K
Director and President of Europe & Immunology...
Total Annual Compensation: C$343.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: C$245.0K
Compensation as of Fiscal Year 2013.

nuvo research inc (NRI) Key Developments

Nuvo Research Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Nuvo Research Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of CAD 3.4 million against CAD 3.7 million for the same period in the last year. Net loss was CAD 6.1 million or CAD 0.56 per diluted share against CAD 1.9 million or CAD 0.22 per diluted share for the same period in the last year. The decrease in revenue was attributable to lower royalty revenue primarily from Pennsaid and Pennsaid 2% net sales in the U.S. market.  The decrease in royalty revenue was partially offset by an increase in product sales to Horizon to prepare for their launch of Pennsaid 2% in January 2015. Cash provided by operating activities was CAD 7.3 million for the three months ended December 31, 2014 compared to cash used in operating activities of CAD 1.7 million for the three months ended December 31, 2013. For the year, the company reported revenue of CAD 13.1 million against CAD 18.4 million for the same period in the last year. Net income was CAD 38.6 million or CAD 3.76 per diluted share against net loss of CAD 10.4 million or CAD 1.17 per diluted share for the same period in the last year. For the year ended December 31, 2014, cash provided by operating activities was CAD 2.6 million compared to cash used in operating activities of CAD 1.7 million for the year ended December 31, 2013.

Nuvo Research Inc. Auditor Raises 'Going Concern' Doubt

Nuvo Research Inc. filed its Annual on Feb 19, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Nuvo Research Inc. - Special Call

To discuss the results from the WF10 Phase 2 trial

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRI:CN C$4.22 CAD -0.12

NRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,699 GBp +8.00
Endo International PLC $87.81 USD -0.47
Pfizer Inc $34.16 USD -0.14
View Industry Companies
 

Industry Analysis

NRI

Industry Average

Valuation NRI Industry Range
Price/Earnings 1.1x
Price/Sales 3.3x
Price/Book 0.8x
Price/Cash Flow 1.1x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVO RESEARCH INC, please visit www.nuvoresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.